Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 13/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17437330 | 0.85 | ADORA3 (0.32) | CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17437345 | 0.82 | CYP11B1 (0.35) | CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17437327 | 0.80 | ADORA3 (0.39) | RPS6KA5JAK2JAK1 | |
| SCHEMBL17437529 | 0.79 | CYP11B2 (0.37) | CYP3A4ALDH1A1CYP1A2CYP2C19CYP11B2 | |
| SCHEMBL17437486 | 0.78 | SLC9A1 (0.33) | CYP3A4ALDH1A1CYP1A2CYP2C19CYP11B2 | |
| SCHEMBL17437544 | 0.78 | RPS6KA5 (0.36) | CYP1A2RPS6KA5 | |
| SCHEMBL17437575 | 0.77 | RPS6KA5 (0.48) | CYP3A4ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17437314 | 0.76 | TLR8 (0.34) | RPS6KA5 | |
| SCHEMBL17437312 | 0.74 | KDM4E (0.34) | ALDH1A1CYP11B2CYP11B1JAK2JAK1 | |
| SCHEMBL17437480 | 0.74 | KDM4E (0.34) | CYP3A4ALDH1A1CYP1A2RPS6KA5JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050963-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-02-23 | — | — | US | disclosed |
| US-9512120-B2 | Microbicidally active imidazopyridine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-06 | — | — | US | disclosed |
| US-20160016949-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050963-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | IDO1, IDO2, FOXM1 | CYP3A4 59/4885ALDH1A1 928/4885CYP1A2 25/4885 |
| US-20160016949-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | IDO1, IDO2, FOXM1 | CYP3A4 59/4885ALDH1A1 928/4885CYP1A2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.